EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comedications Associated with Immune‐Related Adverse Events from Immune‐Checkpoint Inhibitors

Léonard Laurent iD, Baptiste Abbar iD, Kevin Bihan iD, Elise Dumas iD, Floriane Jochum iD, Bénédicte Lebrun-Vignes, Jean-Philippe Spano iD, Joe-Elie Salem iD, Anne-Sophie Hamy iD, Fabien Reyal iD, Paul Gougis iD

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Léonard Laurent und 10 weiteren Autor:innen. Beteiligte Einrichtung: Residual Tumor & Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Université Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Drug-Related Side Effects and Adverse Reactions, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Contrats ED: Programme Blanc Institut Curie PSL Academic Program, Fondation ARC Pour la Recherche Sur le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune‐checkpoint inhibitors (ICI) have revolutionized cancer treatment but are responsible for various immune‐related adverse events (irAE). The impact of non‐anticancer medications (comedications) on irAE occurrence remains largely unexplored. The objective of this study was to assess comedications associated with an increased reporting of irAE with ICIs. In this pharmacovigilance study, all individual case safety reports (ICSRs) involving ICIs reported in the World Health Organization international pharmacovigilance database Vigibase up to January 2024 were extracted. All suspect or interacting comedications were analyzed individually and as drug classes using Anatomical Therapeutic Chemical classification level 4. The primary outcome was the reporting odds ratio (ROR) of irAE in patients who received both an ICI and the comedication of interest, compared with ICI‐treated patients who did not receive that comedication. Among 169,753 ICSRs involving an ICI, a total of 314,366 comedications were recorded, with 8,122 identified as “suspect or interacting.” Analysis shows an increased reporting of nephritis with proton pump inhibitors (PPI) (ROR = 29.62 [95% CI = 18.61–47.14]) and with non‐steroidal anti‐inflammatory drugs (ROR = 10.47 [95% CI = 4.15–26.41]), myositis with statins (ROR = 9.41 [95% CI = 3.50–25.30]), ketoconazole with hepatitis (ROR = 20.49 [95% CI = 1.53–274.17]) and autoimmune bullous disease with dipeptyl‐peptidase‐4 inhibitors (ROR = 46.42 [95% CI = 11.71–184.05]), among others. Various drugs, including PPI (ROR = 8.61 [95% CI = 3.48–21.26]), some anti‐infectives (sulfamethoxazole, ROR = 31.31 [95% CI = 13.32–73.61], clavulanic acid, ROR = 18.12 [95% CI = 4.77–68.89]), allopurinol (ROR = 57.11 [95% CI = 11.27–289.39]) or levetiracetam (ROR = 14.91 [95% CI = 2.15–103.64]) were associated with serious cutaneous adverse reactions. Complementary analysis showed higher ROR in the ICI population versus without ICI for the association of nephritis with ibuprofen (ROR ICI = 27.82 vs. ROR VigiBaseWithoutICI = 3.56, ROR ratio = 7.81 [95% CI = 1.23–49.50]) and myocarditis with influenza vaccine (ROR ICI = 22.74 vs. ROR VigiBaseWithoutICI = 0.66, ROR ratio = 34.45 [95% CI = 1.66–723.24]), suggesting a synergistic toxicity. This study identified multiple comedications associated with an increased reporting of specific irAE. Some of them might be synergistic warranting further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsDrug-Related Side Effects and Adverse ReactionsNeoplasmsHumansPharmacovigilanceMaleFemaleDrug InteractionsAdverse Drug Reaction Reporting SystemsMiddle AgedAgedAdultDatabases, Factual

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Residual Tumor & Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Université Paris Cité, Paris, France.
  • Department of Medical Oncology, Pitié-Salpêtrière Hospital, Sorbonne Université, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.
  • Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Inserm U1135, Sorbonne Université, Paris, France.
  • Department of PharmacologyInstitut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hôpitaux de Paris (AP-HP), Clinical Investigation Center (CIC-1901), Regional Pharmacovigilance Centre,…
  • Department of Mathematics, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
  • Department of Gynecology, Strasbourg University Hospital, Strasbourg, France.

ORCID-Profile: Léonard Laurent, Baptiste Abbar, Kevin Bihan, Elise Dumas, Floriane Jochum, Jean-Philippe Spano, Joe-Elie Salem, Anne-Sophie Hamy, Fabien Reyal, Paul Gougis

Förderung

  • Contrats ED: Programme Blanc Institut Curie PSL Academic Program
  • Fondation ARC Pour la Recherche Sur le Cancer

Zitieren

APA

Laurent, L., Abbar, B., Bihan, K., Dumas, E., Jochum, F., Lebrun-Vignes, B., Spano, J. P., Salem, J. E., Hamy, A. S., Reyal, F., & Gougis, P. (2025). Comedications Associated with Immune‐Related Adverse Events from Immune‐Checkpoint Inhibitors. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3721

Vancouver

Laurent L, Abbar B, Bihan K, Dumas E, Jochum F, Lebrun-Vignes B, et al. Comedications Associated with Immune‐Related Adverse Events from Immune‐Checkpoint Inhibitors. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3721

BibTeX
@article{Laurent2025,
  author = {Laurent, Léonard and Abbar, Baptiste and Bihan, Kevin and Dumas, Elise and Jochum, Floriane and Lebrun-Vignes, Bénédicte and Spano, Jean-Philippe and Salem, Joe-Elie and Hamy, Anne-Sophie and Reyal, Fabien and Gougis, Paul},
  title = {Comedications Associated with Immune‐Related Adverse Events from Immune‐Checkpoint Inhibitors},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3721}
}
Kostenlos starten →